$1.55
0.03[1.97%]
At close: Apr 26
$1.55
0[0.00%]
PreMarket: 8:22AM EDT
Atossa Therapeutics
(NASDAQ:ATOS)Atossa Therapeutics Stock (NASDAQ:ATOS), Analyst Ratings, Price Targets, Predictions
Atossa Therapeutics Inc has a consensus price target of $4.5, established from looking at the 4 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 16, 2024, April 2, 2024, and February 12, 2024. With an average price target of $4 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 158.06% upside for Atossa Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Atossa Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | ATOS | Buy Now | Atossa Therapeutics | $1.55 | 158.06% | HC Wainwright & Co. | Emily Bodnar | → $4 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | ATOS | Buy Now | Atossa Therapeutics | $1.55 | 158.06% | HC Wainwright & Co. | Emily Bodnar | $4 → $4 | Maintains | Buy | Get Alert |
| 02/12/2024 | ATOS | Buy Now | Atossa Therapeutics | $1.55 | 158.06% | HC Wainwright & Co. | Emily Bodnar | → $4 | Initiates | → Buy | Get Alert |
| 09/08/2023 | ATOS | Buy Now | Atossa Therapeutics | $1.55 | 222.58% | Cantor Fitzgerald | Louise Chen | → $5 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Atossa Therapeutics (ATOS)?
The latest price target for Atossa Therapeutics (NASDAQ: ATOS) was reported by HC Wainwright & Co. on April 16, 2024. The analyst firm set a price target for $4.00 expecting ATOS to rise to within 12 months (a possible 158.06% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atossa Therapeutics (ATOS)?
The latest analyst rating for Atossa Therapeutics (NASDAQ: ATOS) was provided by HC Wainwright & Co., and Atossa Therapeutics reiterated their buy rating.
When was the last upgrade for Atossa Therapeutics (ATOS)?
There is no last upgrade for Atossa Therapeutics.
When was the last downgrade for Atossa Therapeutics (ATOS)?
There is no last downgrade for Atossa Therapeutics.
When is the next analyst rating going to be posted or updated for Atossa Therapeutics (ATOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating Atossa Therapeutics (ATOS) correct?
While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a reiterated with a price target of $0.00 to $4.00. The current price Atossa Therapeutics (ATOS) is trading at is $1.55, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.